SCHEMBL8560415

SCHEMBL8560415

CCC(C)NC1CCc2[nH]c3ccc(NC(=S)N(OC(C)=O)C(C)C)cc3c2C1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.44
HTR1B P28222 2/20 0.44
HTR1D P28221 1/20 0.44
HTR1F P30939 1/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
HTR1E P28566 1/20 0.42
HTR7 P34969 1/20 0.42
OPRM1 P35372 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8555878 0.87 HTR1F (0.42) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL8110515 0.85 HTR1A (0.43) HTR1AHTR1BHTR1DHTR1FDRD2
Acetic Acid SCHEMBL8560412 0.82 HTR1A (0.43) HTR1AHTR1BHTR1DHTR1FDRD2
Sulfuric Acid SCHEMBL8110582 0.80 HTR1A (0.45) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL7662558 0.78 HTR1F (0.67) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL8110315 0.78 HTR1F (0.52) HTR1AHTR1BHTR1DHTR1FDRD2
Hydrochloric Acid SCHEMBL7666106 0.78 HTR1F (0.66) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL8101124 0.77 JAK2 (0.47) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL8100843 0.77 HTR1F (0.49) HTR1AHTR1BHTR1DHTR1FDRD2
SCHEMBL8116377 0.75 F2R (0.47) HTR1AHTR1BHTR1DHTR1FALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
US-5814653-A SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS ELI LILLY AND COMPANY (US) 1998-09-29 US disclosed
US-5708187-A MIGRANE HEADACHES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0749962-A1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles ELI LILLY AND COMPANY (US) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D HTR1A 2/4885HTR1B 4/4885HTR1D 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.